|Bid||0.000 x 116300|
|Ask||0.000 x 111900|
|Day's Range||0.000 - 0.000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Repros Therapeutics Inc (NASDAQ:RPRX), a USD$25.52M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
Pharmaceutical giant Allergan PLC (AGN) will acquire The Woodlands-based Repros Therapeutics Inc. (RPRX), a company that develops drugs to treat male and female reproductive disorders, according to a Dec. 12 press release. A subsidiary of Ireland-based Allergan will purchase all of the outstanding shares of Repros common stock through a cash tender offer for 67 cents per share. Allergan — formerly Actavis PLC — reported net revenue of $14.57 billion in 2016, according to its annual report.
Today, I will be analyzing Repros Therapeutics Inc’s (NASDAQ:RPRX) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
For Repros Therapeutics Inc’s (NASDAQ:RPRX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. RPRX is exposedRead More...
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $304,000 in the period. The company's shares closed at 41 cents. ...
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
The The Woodlands, Texas-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $7,000 in the period. The company's shares closed at 35 cents. A year ago, ...
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $7,000 in the period. In the final minutes of trading on Tuesday, ...
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $5,000 in the period. For the year, the company reported that ...